News
Why Advanced Drainage Stock Is Floating Higher Today
Advanced Drainage Systems (NYSE: WMS) beat top- and bottom-line expectations for the quarter, and announced a dividend hike. Investment dollars are flowing into the stock, sending shares of the
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the
Is AT&T Stock a Buy for 2024?
With 2024 upon us, telecom stalwart AT&T (NYSE: T) looks like it's turned a corner on a multi-year transformation. After John Stankey took over as CEO in July 2020, he refocused the company on its
2 Healthcare Stocks to Buy Hand Over Fist in February
Many investors believe in the January Effect, or the idea that the stock market tends to go on a run during the first month of the year. Whether or not this effect is real, investing in a company
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood trounced the market in 2020, with her aggressive investing style helping Ark Invest's family of exchange-traded funds outperform. She beat the market again in 2023 after back-to-back
Pfizer's Problems Go Far Beyond Just Declining COVID Revenue
A lot can change on the stock market in just a few years, and Pfizer (NYSE: PFE) is a great example. At the end of 2021, its shares were trading at around $60, and things were looking great for the
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q4 2023 Earnings CallFeb 06, 2024, 5:00 p.m. ET
Operator
Source Fool.com
Why Coherus BioSciences Stock Jumped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) climbed 14.9% on Tuesday after the company announced a positive revision to the terms of its loan agreement with Pharmakon Advisors.
In a press release
Where Will AT&T Stock Be in 2024?
Fool.com contributor Parkev Tatevosian highlights where be believes AT&T (NYSE: T) stock could be in one year.
*Stock prices used were the afternoon prices of Feb. 3, 2024. The video was published
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it's on track to do so again in the field of pain relief. With the latest clinical-trial data
This High-Flying Stock Just Got Some Bad News: Should You Sell?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) ended 2023 with an important regulatory approval. The company's gene-editing therapy for a duo of blood-related disorders, Casgevy, earned the nod
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q4 2023 Earnings CallFeb 05, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Why AbbVie Stock Flew Higher on Monday
Still basking in the afterglow of an encouraging quarterly earnings report, AbbVie (NYSE: ABBV) stock saw a healthy 1.5% rise in price across Monday's trading session. What helped was a series of
Why Catalent Stock Soared Today
Shares of Catalent (NYSE: CTLT) rose by 9.7% on Monday after the pharmaceutical contract manufacturing and drug delivery technology specialist agreed to be acquired by Novo Holdings, the parent
Why Novo Nordisk Stock Crushed the Market on Monday
A major acquisition by its controlling shareholder pushed Novo Nordisk's (NYSE: NVO) U.S.-listed shares 4% higher on Monday. As a result of the deal, Novo Nordisk will acquire from that shareholder
EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
Got $3,000? 2 Tech Stocks to Buy and Hold for the Long Term
One of the more important qualities an investor can have is patience. The stock market is volatile, and even great companies see their stock prices go through down periods. What's important, though
2 Stocks to Buy Near Their 52-Week Highs
When is it time to buy a stock? One of the best-known pieces of investing advice tells us to buy low and sell high. But what constitutes "low" is relative. A stock near its 52-week high can still be
The Bull Market Left These 3 Stocks Behind, but They're Buys Right Now
With the stock market recently hitting new all-time highs again, times are exciting for people who are fully invested, but these conditions can be more frustrating for those who have cash available
2 Healthcare Dividend Kings to Buy and Hold Forever
Dividend Kings are unquestionably among the top picks for income-seeking investors. These are companies that have increased their payouts for at least 50 consecutive years, which strongly suggests
Could AT&T Stock Finally Surge Past $20 in 2024?
Shares of telecom giant AT&T (NYSE: T) have been stuck in a downtrend since the start of the pandemic in 2020. From peak to trough, the stock was down more than 50% at one point during 2023.
The
3 Fabulous Dividend Stocks to Buy in February
Any time is a good time to buy solid dividend stocks. But this month is a special time to do so for one simple reason: There's an extra day for investors to buy stocks because it's a leap year.
Is Nvidia Stock a Buy Now?
Nvidia (NASDAQ: NVDA) won over Wall Street last year, illustrated by its more than 210% stock growth since January 2023.
The company's years of dominance in graphics processing units (GPUs)